Day: June 4, 2024

The Agtech company and organic food producer AUGA group, AB (hereinafter the Company) is continuing its employee motivation scheme through share options and is also implementing the 2021 stock option programme for employees. 2 052 236 shares have been granted to 193 employees. The Company launched its first option programme in spring 2019. Almost 2.55 million of shares were allocated to employees in the first year and additional 2.23 million of shares in 2020, 2.38 million of shares in 2021, 1.65 million of shares in 2022, 2.18 million of shares in 2023 Employees who signed the share option contracts in 2021, this year will have the right to vest them. The decision to increase the Company’s authorized capital by issuing new ordinary registered shares, that will be transferred free of charge to employees who have submitted relevant...

Minneapolis, MN, June 04, 2024 (GLOBE NEWSWIRE) — Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, is set to join the Russell 2000® Index and the broad-market Russell 3000® at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for...

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of ZEPIZURE® until the next value creation milestones, in particular the EUA approval by the FDA Dijon, France 4 April, 2024 — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces the successful closing of its rights offering with maintenance of preferential subscription rights for a gross amount of approximately €8 million as announced on 30 April 2024. The net proceeds from this round are approximately €7.6 million. This round of financing is an important step to continue to support Crossject’s activities in bringing its ZEPIZURE® emergency epilepsy...

Beverly Hills, California, June 04, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today the appointment of Peter Severin as Chairman of the Board of Directors. Peter Severin replaces Christian Hill-Madsen as Chairman, who resigned to focus on developing the next generation of periodontities therapies for Orocidin A/S, a company owned 95% by Nordicus, where Christian currently serves as Chairman of its Board. “We are delighted to welcome Peter as Chairman of the Board,” said Henrik Rouf, CEO of Nordicus. “His broad sales experience in the life sciences industries in the Nordics will be invaluable to Nordicus...

ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) — The attached notifications relate to the annual equity incentive awards granted to directors of the Company, as well as the one-time equity incentive awards issued to new directors upon their election to the board of directors of the Company.AttachmentsNotification of managers’ transaction – Ackermann – 2024 annualNotification of managers’ transaction – Khanani – new directorNotification of managers’ transaction – Rosenberg – 2024 annualNotification of managers’ transaction – Warner – new director

Reykjavik, June 04, 2024 (GLOBE NEWSWIRE) — “Amaroq” or the “Company” Total Voting Rights, PDMR Notification and Stock Option Awards TORONTO, ONTARIO – 4 June 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, announces that, following the exercise of options, its share capital consists of 327,418,727 common shares of no par value each as at 3 June 2024, each with voting rights. Given the Company does not hold any common shares in Treasury, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in interest in, the share capital of the Company. Amaroq Minerals Ltd....

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82% Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of care Company will host a conference call at 4:15 p.m. ET todayNEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,...

Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET). This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolidation. The convening notice and other documents pertaining to the shareholders’ meeting, can be consulted on Oxurion’s website Oxurion/shareholders. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium....

Following the signing of an agreement to sell 100% of TM tryggingar hf. to Landsbankinn hf., and the anticipated changes to the Kvika group (“Kvika” or “the bank”), the office of the CEO has been restructured. Sigurður Viðarsson, deputy director of Kvika, has reached an agreement on retirement from the bank. The position of deputy CEO will subsequently be abolished, and tasks will be transferred to other managers in the bank. Sigurður will assist with the transition, ensuring a smooth handover of projects, and will remain on the boards of companies within the Kvika group until autumn. Sigurður started as CEO of TM in October 2007 and fulfilled that role continuously from 2007 until he took over as deputy CEO of Kvika at the end of 2022. Magnús Þór Gylfason, director of communications and stakeholder relations, has...

Not for distribution in the United States, Canada, Australia or Japan Syensqo successfully completes the placement of its inaugural US$ 1.2 billion USD-denominated bond offering  Brussels, Belgium – June 4, 2024 – 19:15 CEST Syensqo today announces that it has successfully closed a senior bond issuance for a nominal amount of US$ 1.2 billion across two tranches:US$ 600 million bond, with a 5-year maturity and a 5.65% fixed coupon US$ 600 million bond, with a 10-year maturity and a 5.85% fixed couponThe rating for the bonds is BBB+ by S&P and Baa1 by Moody’s. The transaction was met with strong interest, with an orderbook more than 4x oversubscribed, exceeding US$ 5 billion, and participation from more than 125 institutional investors.  Proceeds will be used for general corporate purposes, including the repayment of...